1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Shine-On Biomedical Co., Ltd.

Shine-On Biomedical Co., Ltd.

TTPEX:6926
65.40
TWD
-0.10
(-0.15%)
3.17BMarket Cap
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.19
- -
0.6
- -
Basic EPS, GAAP
- -
- -
-0.46
-0.43
-0.75
-2.39
-2.21
- -
Free Cash Flow per Basic Share
- -
- -
-0.5
-0.54
-0.55
-1.85
-2.33
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
18.22
23.57
22.82
20.43
18.22
15.89
Tangible Book Value per Share
- -
- -
18.2
23.5
22.75
20.36
18.04
15.71
Basic Weighted Avg Shares
50
43
18
45
50
50
50
50
Sales/Revenue/Turnover
- -
- -
- -
- -
10
- -
30
- -
Operating Margin (%)
- -
- -
- -
- -
-658.16
- -
-418.33
- -
Depreciation Expense
- -
- -
1
2
2
2
2
- -
Net Income, GAAP
- -
- -
-8
-20
-37
-119
-110
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
-390.22
- -
-367.62
- -
Working Capital
- -
- -
904
1,166
1,130
1,012
892
776
LT Debt
- -
- -
2
1
- -
1
- -
- -
Total Equity
- -
- -
908
1,174
1,136
1,018
907
791
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-1.86
-1.88
-3.22
-11.04
-11.46
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
50
50
50
Market Capitalization
3,297
3,486
3,172

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
973
935
835
Cash, Cash Equivalents & STI
957
922
809
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
44
59
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-10.84%
Free Cash Flow
- -
- -
25.78%
Net Income, GAAP
- -
- -
-7.24%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
30
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-2.39
2025
- -
- -
-2.21
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hung Che Chiang
Full Time Employees
23
Sector
Health technology
Industry
Biotechnology
Address
No. 633, Taiwan Avenue Taichung TX Taiwan 407
IPO Date
Nov 25, 2022
Website
shineon-bio.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Shine-On BioMedical Co., Ltd. (6926.TWO) researches, develops, and manufactures anti-cancer new drug products, focusing on antibody therapeutics and nucleic acid drugs delivered via exosomes. The company offers trispecific T cell engaging nanobody (SOA101), EphA10 trispecific antibody engaging immune cells (SOA201), iNb intrabody nanoscale intracellular specific antibody drug (SOA102), iNb STAR TriTE T cell receptor nanoscale trispecific antibody drug (SOA103); and nucleic acid drugs including exosome-carrying nucleic acid and chemotherapy drugs (SOB101). Founded in April 2021 by Dr. Chiu-Chin Huang and headquartered at 5/F-6, 633 Section 2, Taiwan Boulevard, Taichung, Taiwan, it listed on the Emerging Stock Market of the Taipei Exchange in November 2022 and employs 22 staff targeting oncology indications such as solid tumors, ovarian cancer, and glioblastoma primarily in Taiwan. Shine-On BioMedical leverages two patented platforms: Tri-Specific Antibody with T-cell Engager technology and Targeted Exosome for Drug Delivery, with SOA101 advancing to Phase 1/2 clinical trials for locally advanced malignant solid neoplasms and recruiting patients. Recently, the company licensed its patented exosome small-molecule drug loading technology to ESCO Aster; founder Chiu-Chin Huang received the New Academy Member honor from the Industrial Technology Research Institute's Industry Academy; and it continues preclinical development of SOB-101 and SOB-102 alongside pipeline expansion.